Santen Publishes its Annual Integrated Report “Santen Report 2026”

October 7, 2026 - Osaka, Japan - Santen Pharmaceutical Co., Ltd. (hereinafter Santen) today announced the release of the Japanese and English versions of Santen Report 2026, its integrated report for the fiscal year ended March 31, 2026.

Under the FY2025-2029 Medium-Term Management Plan, Santen is shaping the future of eye care while charting a course for long-term value creation and sustainable growth. This year’s report highlights how Santen has been working with patients, healthcare professionals, and the broader ophthalmic community to address unmet needs amid a rapidly evolving eye care market. The report also explores the business and financial strategies that have placed Santen on a trajectory of sustainable growth. 

The report is available on Santen’s corporate website:
https://www.santen.com/en/ir/document/annual

About Santen
Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen’s products and services are available in more than 60 countries and regions. Guided by its Core Principle “Tenki ni sanyo suru” – Exploring the secrets and mechanisms of nature in order to contribute to people’s health – Santen combines its expertise with deep patient focus to contribute to the realization of “Happiness with Vision.”
For more information, please visit https://www.santen.com/en.

For media inquiries:
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com